2018
DOI: 10.1177/1756284818808072
|View full text |Cite
|
Sign up to set email alerts
|

New drug developments in metastatic gastric cancer

Abstract: Metastatic gastric cancer is associated with a poor prognosis and novel treatment options are desperately needed. The development of targeted therapies heralded a new era for the management of metastatic gastric cancer, however results from clinical trials of numerous targeted agents have been mixed. The advent of immune checkpoint inhibitors has yielded similar promise and results from early trials are encouraging. This review provides an overview of the systemic treatment options evaluated in metastatic gast… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
13
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(13 citation statements)
references
References 95 publications
(104 reference statements)
0
13
0
Order By: Relevance
“…Over the last decades, great efforts have been made to provide novel understanding involving the early diagnosis, targeted therapy, and prognostic evaluation of GC 10,11. However, the overall survival time of GC patients remains unfavorable, particularly in some developing countries 12,13.…”
Section: Discussionmentioning
confidence: 99%
“…Over the last decades, great efforts have been made to provide novel understanding involving the early diagnosis, targeted therapy, and prognostic evaluation of GC 10,11. However, the overall survival time of GC patients remains unfavorable, particularly in some developing countries 12,13.…”
Section: Discussionmentioning
confidence: 99%
“…Although a decreasing incidence of GC was observed in many countries due to the changes in eating habits and environment, GC remains prevalent in East Asia, especially in China, Japan and Korea [2]. Despite some advances in the diagnosis and treatment, the GC patients’ clinical outcome has not improved significantly at present [3]. In most countries, the 5-year overall survival rate for GC patients remains below 20% [4].…”
Section: Introductionmentioning
confidence: 99%
“…GC is a common upper gastrointestinal tumor type ( 27 ). Given the atypicality of clinical symptoms, numerous patients are already in the stage of advanced metastasis at the time of clear diagnosis and metastatic GC is closely related to poor prognosis ( 28 ). An effective treatment plan for GC is necessary.…”
Section: Discussionmentioning
confidence: 99%
“…At present, with the emergence of various biomarkers for GC, such as VEGFR2( 29 ), VEGF ( 30 , 31 ), EGFR ( 32 ), MET ( 33 ), PIK3CA ( 34 ) and mTOR ( 35 ), the corresponding targeted drugs have brought new hope regarding the OS of patients. Successful biomarkers require to be cost-effective and reproducible, but to date, challenges in identifying suitable predictive biomarkers have hampered the success of numerous targeted therapies for GC ( 28 ). Therefore, it is necessary to discover novel biomarkers that may accurately predict patient outcomes and allow for better treatment and follow-up decisions.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation